Pediatrics · Medical Literature
Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Trial.
Abstract
Mycoplasma pneumoniae (MP) is a major cause of community-acquired pneumonia in children, with increasing macrolide resistance complicating treatment. Traditional Chinese Medicine (TCM) provides unique benefits for pediatric respiratory infections. To evaluate the safety and efficacy of Lianhua Qingke (LHQK) tablets as adjunctive therapy in children with M. pneumoniae pneumonia (MPP). This prospective, multicenter, randomized, double-blind, placebo-controlled trial adhered to the Declaration of Helsinki and was registered in the Chinese Clinical Trial Registry (ChiCTR2300078209). A total of 160 children aged 4-14 years with mild MPP were randomized 1:1 to receive conventional therapy plus LHQK or conventional therapy plus placebo for 7 days across 13 hospitals over 4 months. Efficacy analysis included 128 participants with centrally confirmed MP infection; safety analysis included all 160. Baseline characteristics were comparable (all p > 0.05), with 98.8% medication compliance in both groups (p > 0.05). The primary outcome was the major symptom resolution rate by Day 7. The LHQK group showed a significantly higher major symptom resolution rate (85.9% vs. 65.6%, p 0.05), with no serious events reported. LHQK is a safe and effective adjunctive TCM therapy for mild MPP in children, offering significant benefits in respiratory symptom alleviation and a favorable safety profile, with a trend toward shorter recovery time, providing a valuable treatment option amid rising antibiotic resistance.
Clinical relevance
In children aged 4–14 years with mild Mycoplasma pneumoniae pneumonia (MPP), does Lianhua Qingke (LHQK) tablets added to conventional therapy improve major symptom resolution by Day 7 compared with conventional therapy plus placebo? __SNAPSHOT__ {"studyDesign":"Prospective, randomized, double-blind, multicenter, placebo-controlled trial","setting":"China; 13 hospitals (multicenter inpatient/outpatient pediatric settings); conducted over 4 months","sampleSize":"n=160 randomized 1:1 (LHQK: ~80, placebo: ~80); efficacy analysis n=128 (centrally confirmed MP infection); safety analysis n=160","population":"Children aged 4–14 years with mild Mycoplasma pneumoniae pneumonia; baseline characteristics comparable between groups (all p > 0.05); macrolide-resistant cases not separately reported","intervention":"Conventional therapy plus Lianhua Qingke (LHQK) tablets for 7 days","comparator":"Conventional therapy plus matched placebo for 7 days","primaryOutcome":"Major symptom resolution rate by Day 7","followUp":"7 days (treatment period); duration of post-treatment follow-up not reported","fundingSource":"Not reported in abstract; trial registered in Chinese Clinical Trial Registry (ChiCTR2300078209); LHQK is a product of Shijiazhuang Yiling Pharmaceutical — potential industry affiliation not explicitly disclosed in available abstract"}
Key findings
In the efficacy-evaluable population (n=128, centrally confirmed MP infection), the LHQK group demonstrated a statistically significantly higher major symptom resolution rate by Day 7 compared with placebo (85.9% vs. 65.6%; p 0.05). Regarding safety, the adverse event incidence was numerically lower in the LHQK group (2.5% vs. 8.8%; p > 0.05); no serious adverse events were reported in either group. Confidence intervals for any outcome were not reported in the available abstract.
Practice implications
This trial establishes that adjunctive LHQK tablets, added to conventional therapy, significantly improved the rate of major symptom resolution at Day 7 in children with centrally confirmed mild MPP, with an absolute difference of ~20 percentage points and an NNT of ~5 (calculated). The improvement in cough and expectoration relief rates was statistically significant, though the reduction in median time to resolution (0.5 days) did not reach significance, raising questions about clinical meaningfulness of the symptomatic benefit magnitude. The study applies to children aged 4–14 years with mild MPP in a Chinese hospital setting and does not establish efficacy in severe MPP, in children outside this age range, or in non-Chinese pediatric populations with potentially different baseline microbiome, antibiotic practices, or disease severity distributions. Macrolide-resistant subgroups were not reported separately, limiting conclusions in this clinically critical subpopulation despite macrolide resistance being a stated motivation for the study. Longer-term outcomes (radiographic resolution, recurrence, hospitalization rates) were not assessed. Only the abstract is available for this review; full publication data including confidence intervals, subgroup analyses, and complete safety reporting are necessary before definitive clinical recommendations can be made. Practice change is premature; the findings are hypothesis-generating and warrant confirmation. __LIMITATIONS__ Only the abstract is available; full methods, complete statistical reporting (confidence intervals, adjusted analyses), and safety data cannot be independently verified.,Efficacy population (n=128) was smaller than the randomized population (n=160) due to restriction to centrally confirmed MP infection — the basis and timing of central confirmation, and whether this created differential attrition bias, are not reported.,Short follow-up of 7 days only; no data on radiographic outcomes, hospitalization, relapse, or longer-term safety.,Conducted exclusively in China across 13 hospitals; generalizability to non-Chinese pediatric populations with different antibiotic resistance patterns and treatment norms is uncertain.,The 0.5-day reduction in median symptom resolution time (4.5 vs. 5.0 days, p = 0.072) was not statistically significant, which limits interpretation of the primary resolution rate finding as clinically meaningful in isolation.,Macrolide-resistant MPP subgroup was not separately analyzed, despite this being a key clinical rationale for the trial.,Funding source and potential industry relationships with the LHQK manufacturer (Shijiazhuang Yiling Pharmaceutical) are not explicitly disclosed in the available abstract, representing an unresolved conflict-of-interest concern.,Conventional therapy was not standardized in the abstract, introducing heterogeneity in the comparator arm.,No confidence intervals reported for any outcome measure; statistical robustness of findings cannot be fully evaluated.,Study duration of 4 months across 13 sites may have introduced seasonal or site-level variability in MP epidemiology and disease severity. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In children aged 4–14 years with mild, centrally confirmed MPP, adjunctive LHQK tablets significantly increased major symptom resolution at Day 7 (85.9% vs. 65.6%; NNT ~5 [calculated]) with no serious adverse events. However, the 0.5-day difference in median resolution time was not statistically significant, confidence intervals are unreported, follow-up was limited to 7 days, and the study was conducted exclusively in China without macrolide-resistance subgroup data. These results are promising but require independent replication with full reporting before LHQK can be recommended as standard adjunctive therapy for pediatric MPP.